EPISODE · Dec 21, 2021 · 48 MIN
Booster shots and pediatric vaccines with Dr. Peter Marks
from Moving Medicine · host Aly Schweigert
Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research at the FDA, joins Susan R. Bailey, MD, immediate past president of the AMA, to discuss the data and recommendations for Pfizer, Moderna and Janssen booster shots. Dr. Marks walks through the safety and efficacy data supporting the recent authorization of the Pfizer pediatric vaccine for 5- to 11-year-old children. This episode was part of an AMA webinar recorded prior to the emergence of the Omicron variant. ⭐⭐⭐⭐⭐ 🩺 The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most — patients. We will meet this challenge together. Join us: https://ama-assn.co/JoinRenew 🥼 Go to https://ama-assn.co/FightingForDocs to learn more about our AMA advocacy priorities, including: ▹ Reforming Medicare payment ▹ Fighting scope creep ▹ Fixing prior authorization ▹ Reducing physician burnout ▹ Making technology work for physicians 📺 Subscribe to @americanmedicalassociation on YouTube: https://ama-assn.co/youTube 📧 Sign up for #MorningRounds and free daily newsletters from the AMA: https://ama-assn.co/Newsletters 💬 Follow #AMA on social media: https://ama-assn.co/Social
What this episode covers
Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research at the FDA, joins Susan R. Bailey, MD, immediate past president of the AMA, to discuss the data and recommendations for Pfizer, Moderna and Janssen booster shots. Dr. Marks walks through the safety and efficacy data supporting the recent authorization of the Pfizer pediatric vaccine for 5- to 11-year-old children. This episode was part of an AMA webinar recorded prior to the emergence of the Omicron variant.
NOW PLAYING
Booster shots and pediatric vaccines with Dr. Peter Marks
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·12m
Mar 26, 2026 ·13m
Feb 17, 2026 ·56m
Feb 10, 2026 ·50m
Feb 5, 2026 ·11m